Table 4.
Summary of findings table
| Summary of findings | ||||||
| Effectiveness and safety of difluprednate compared with prednisolone acetate after cataract surgery | ||||||
| Patient or population: patients who underwent cataract surgery Intervention: difluprednate Comparison: prednisolone acetate | ||||||
| Outcomes | Anticipated absolute effects*(95% CI) | Relative effect (95% CI) |
No of participants (studies) |
Certainty of the evidence (GRADE) |
Comments | |
| Risk with prednisolone acetate | Risk with effectiveness of difluprednate | |||||
| Absence of AC cells or grade 0 at 15±2 days | 641 per 1000 |
816 per 1000
(648 to 914) |
OR 2.48
(1.03 to 5.93) |
779 (5 RCTs) |
⨁⨁◯◯ LOW*† |
|
| Absence of AC flare or grade 0 at 15±2 days | 679 per 1000 |
884 per 1000
(703 to 961) |
OR 3.60
(1.12 to 11.62) |
379 (4 RCTs) |
⨁⨁◯◯ LOW‡§ |
|
| Absence of corneal oedema at 15±2 days | 732 per 1000 |
799 per 1000
(636 to 901) |
OR 1.46
(0.64 to 3.34) |
604 (3 RCTs) |
⨁⨁⨁◯ MODERATE¶ |
|
| Absence of corneal oedema at 30±2 days | 754 per 1000 |
794 per 1000
(600 to 909) |
OR 1.26
(0.49 to 3.27) |
504 (2 RCTs) |
⨁⨁⨁◯ MODERATE** |
|
| High IOP (≥21 mm Hg or a change from baseline of ≥10 mm Hg) | 9 per 1000 |
11 per 1000
(3 to 45) |
OR 1.23
(0.29 to 5.18) |
883 (6 RCTs) |
⨁⨁⨁◯ MODERATE** |
|
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
*One RCT has a high risk of bias, while three other RCTs have unclear risk of bias.
†Significant heterogeneity among studies (I2=75 %).
‡Two RCTs have unclear risk of bias.
§Significant heterogeneity among studies (I2=72%).
¶High risk of bias in one RCT and unclear risk in another one.
**High risk of bias in one RCT which has the largest weight.
AC, anterior chamber; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; IOP, intraocular pressure; RCT, randomised-controlled trial.